Lantheus appoints new Chief Commercial Officer

  • Investing.com
  • Stock Market News
Lantheus appoints new Chief Commercial Officer
Credit: © Reuters.

BEDFORD, Mass. - Lantheus (NASDAQ: LNTH ) Holdings, Inc. (NASDAQ: LNTH), a company specializing in radiopharmaceuticals, announced the promotion of Amanda Morgan to Chief Commercial Officer, effective March 25, 2024. Morgan, who has been with Lantheus since November 2022 as Senior Vice President of Commercial, will also join the Executive Team.

In her new role, Morgan will oversee the company's commercial strategy and operations, including Sales, Marketing, Market Access, Commercial Operations, and Customer Experience. She will continue to report to Lantheus President Paul Blanchfield.

Blanchfield commended Morgan for her leadership in expanding the PSMA PET imaging market and establishing PYLARIFY as a preferred agent amidst growing competition. He expressed confidence in her ability to lead the company's commercial endeavors, focusing on value generation for patients, customers, and shareholders.

With over two decades of experience in the healthcare industry, Morgan's career includes significant positions at Acadia Pharmaceuticals and Shire Plc (LON: SHP ), where she supported multi-billion-dollar pharmaceutical businesses. She holds a Bachelor of Business Administration from The University of Iowa.

"I am honored and excited to step into the role of Chief Commercial Officer at Lantheus," Morgan stated. "I am eager to deepen my collaboration with our talented team and advance Lantheus' diverse portfolio of products, always with a primary focus on enhancing patient well-being."

Lantheus is recognized for its commitment to enabling clinicians to diagnose and treat diseases, with a history of over 65 years in providing radiopharmaceutical solutions. The company is headquartered in Massachusetts, with additional offices in New Jersey, Canada, and Sweden.

This announcement is based on a press release statement and contains forward-looking statements that involve risks and uncertainties. The company cautions not to place undue reliance on these statements, which are subject to change based on various factors detailed in filings with the Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles